CMS has signed a license agreement with Sun Pharma for Tildrakizumab, a product used for the treatment of psoriasis and psoriatic arthritis.

Company News

on June 27, 2019,CMS signed 2 license agreements through its wholly-owned subsidiary with a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma) for Sun Pharma’s two products, Tildrakizumab (a psoriasis and psoriatic arthritis) Innovative biotherapeutic products) and 0.09% cyclosporin A eye drops, an innovative therapeutic product for the treatment of dry eye, were

Sun Pharma acquired the global rights to Tildrakizumab in 2014 from a subsidiary of Merck & Co., Inc. in Kenilworth, New Jersey, USA. Based on a successful and critical clinical trial with statistically significant efficacy and clinical sustainability, the product was approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of moderate to severe plaques psoriasis in adults under the trade name ILUMYATM.. The products are also commercialized in Europe and Australia under the trade names ILUMETRITM and ILUMYATM.

0.09% Cyclosporine A Eye Drops is a nanotechnology formulation in a clear, preservative-free aqueous solution developed clinically by Sun Pharma for the treatment of keratoconjunctivitis sicca (dry eye), which has unmet clinical needs in a broad population of patients worldwide. This product is commercialized in the US under the trade name CEQUATM approved by the US Food and Drug Administration (FDA) based on a successful pivotal clinical trial and product that demonstrated statistically and clinically significant improvements in the primary and partial secondary clinical endpoints with rapid onset of action and minor side effects.

Pursuant to the agreement, CMS Group obtained exclusive and sublicensable licenses right for the development and commercialization of the above two products in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan Region) through its wholly-owned subsidiaries. The initial period of the agreement is fifteen years from the initial listing of the product in the region. When the wholly-owned subsidiary of CMS Group has reached a specific conditions stipulated in the agreement, the agreement will be renewed in a three-year period and so on.

The existing product portfolio of the CMS will be enriched and expanded after the two products are marketed in the above regions.

Sun Pharma is the fourth largest professional generics company in the world and the top pharmaceutical company in India. The vertically integrated business and skilled team enable it to deliver high quality products at an affordable price and win the trust of customers and patients in more than 100 countries around the world. Its business is spread across six continents and approved by multiple registration authorities, and it also has a multicultural workforce of people from more than 50 countries. Supported by its strong R&D capabilities of several R&D centers, Sun Pharma promotes excellence through innovation, and its R&D investment accounts for approximately 7% of the company’s annual revenue.